This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Aug 12, 2019 10:19:17 AM
An overview of the evaluation results of the single stage (flash call info) that closed on 16 April 2019 is now available under the "Additional documents" section
Apr 24, 2019 5:20:25 PM
The submission of proposals for topic SC1-BHC-10-2019 (Single-stage) closed on 16 April 2019. More information is now available under the "Topic conditions and documents" section.
27 July 2018 09:25
The submission session is now available for: SC1-BHC-10-2019(PCP).
| Topic identifier: | SC1-BHC-10-2019 | ||
| Publication date: | 27 October 2017 | ||
| Types of action: | PCP Pre-Commercial Procurement | ||
| DeadlineModel: Planned opening date: |
single-stage 26 July 2018 |
Deadline: | 16 April 2019 17:00:00 |
| Time Zone : (Brussels time) | |||
We observe a progressive shift in routine diagnostics, and more particularly in personalised medicine practice, from a growing number of molecular tests to a next generation sequencing approach (NGS). NGS can provide insights on a person’s genetic susceptibility to disease, diagnostic information, and predictive indications about treatment outcome. It also allows to embrace simultaneously different molecular pathways of disease evolution and to identify actionable mutations in a patient for medical decision and further research. In addition, it requires less sample material than multiple tests and therefore reduces risk and inconvenience for patients. However, the introduction of NGS in clinical practice is hampered by its cost, the availability of proper NGS tests, and diagnostic errors resulting from insufficient quality assurance, technological bias and complex interpretation of data.
Scope:The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation. Transferability and cloud based NGS data analyses should be considered, as appropriate. Input from initiatives like the EJP Cofund on rare diseases and ERNs[1] should be considered when relevant. Ethical issues should be addressed.
For grants awarded under this topic for Pre-Commercial procurement it is expected that results could contribute to European or international standards. Therefore, the respective option of Article 28.2 of the Model Grant Agreement will be applied.
The Commission considers that proposals requesting a contribution from the EU of between EUR 9 and 11 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Proposals of this topic should follow the specific requirements for pre-commercial procurement PCP supported by Horizon 2020 grants as set out in General Annex E of the WP.
Expected Impact:Gender
Open Innovation
Innovation Procurement
[1]https://ec.europa.eu/health/ern/policy_en
Horizon 2020 - is a Framework Programme for Research and Technological Development, and is created by the European Union in order to support and encourage research in the European Research Area (ERA). This is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. The Horizon 2020 programme running from 2014 to 2020 has a €79 billion budget (a 46% increase over FP7).
It is structured around three core pillars:
Type of projects: mostly grants, no supplies, no works.
In order to see Horizon 2020 opportunities on DevelopmentAid, please click here.
Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.
Comprises laboratory facilities, equipment, and measurement activities used for scientific, technical, and analytical purposes.
